Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients

This study has been completed.

First Received: February 10, 2004 Last Updated: January 29, 2009 History of Changes

Sponsor:	Actelion
Information provided by:	Actelion
ClinicalTrials.gov Identifier:	NCT00077584

Purpose

To date, one clinical trial, RAPIDS-1, was performed in Scleroderma patients with or without digital ulcers at baseline. The RAPIDS-1 study results showed that Bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of this trial is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24 week treatment period.

Condition	Intervention	Phase
Systemic Sclerosis Scleroderma	Drug: Bosentan	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis

Resource links provided by NLM:

MedlinePlus related topics: Scleroderma

Drug Information available for: Bosentan

U.S. FDA Resources

Further study details as provided by Actelion:

Primary Outcome Measures:

Time to complete healing of the cardinal ulcer up to week 24 whose healing is maintained for 12 weeks
Total number of new digital ulcers per patient up to week 24

Secondary Outcome Measures:

Hand functionality and pain
Tolerability and safety

Estimated Enrollment:	180
Study Start Date:	September 2003
Study Completion Date:	December 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main Inclusion Criteria:

Systemic Sclerosis (SSc), diffuse or limited
SSc patients with at least one digital ulcer at baseline qualifying as a cardinal ulcer.

Main Exclusion Criteria:

Digital ulcers due to conditions other than SSc.
Severe pulmonary arterial hypertension (PAH) (Who class III and IV).
Malabsorption or any severe organ failure (e.g., lung, kidney, liver) or any life- threatening condition.
Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, or prostacyclin analogs) during the past 3 months prior to randomization.
Treatment with inhaled or oral prostanoids one month prior to randomization.
Previous treatment with bosentan.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077584

Show 25 Study Locations

Sponsors and Collaborators

Actelion

Investigators

Principal Investigator:	Carol M. Black, MD	Royal Free Hospital, Centre for Rheumatology, London, UK
Principal Investigator:	Daniel Furst, MD	UCLA School of Medicine, Los Angeles, CA, USA
Principal Investigator:	Joseph H. Korn, MD	Boston University School of Medicine, Boston, MA, USA
Principal Investigator:	Marco Matucci, MD	Universita Degli Studi, E Terapia Medica IV, Florence, Italy
Principal Investigator:	Maureen Mayes, MD	University of Texas, Medical Branch, 6431 Fannin Street, Houston, TX, USA
Principal Investigator:	James Seibold, MD	Robert Wood Johnson Medical School, New Brunswick, NJ, USA

More Information

No publications provided

Study ID Numbers:	RAPIDS-2 / AC-052-331
Study First Received:	February 10, 2004
Last Updated:	January 29, 2009
ClinicalTrials.gov Identifier:	NCT00077584 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Actelion:

Digital Ulcers
Finger Ulcers
Systemic Sclerosis
Scleroderma

Additional relevant MeSH terms:

Pathologic Processes
Skin Diseases
Therapeutic Uses
Connective Tissue Diseases
Scleroderma, Diffuse
Sclerosis

Scleroderma, Systemic
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Bosentan

ClinicalTrials.gov processed this record on November 09, 2009